DNA Stock Summary and Trading Ideas (Ginkgo Bioworks Holdings Class A | NYSE:DNA)

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Ginkgo Bioworks Holdings Class A trades on the NYSE stock market under the symbol DNA.

As of January 16, 2026, DNA stock price declined to $9.55 with 826,161 million shares trading.

DNA has a beta of 3.00, meaning it tends to be more sensitive to market movements. DNA has a correlation of 0.22 to the broad based SPY ETF.

DNA has a market cap of $578.64 million. This is considered a Small Cap stock.

Last quarter Ginkgo Bioworks Holdings Class A reported $39 million in Revenue and -$1.45 earnings per share. This fell short of revenue expectation by $-130,060 and missed earnings estimates by -$.21.

In the last 3 years, DNA traded as high as $101.80 and as low as $5.00.

The top ETF exchange traded funds that DNA belongs to (by Net Assets): VTI, IWM, VXF, KOMP, THNQ.

DNA has underperformed the market in the last year with a return of +2.7%, while the SPY ETF gained +17.9%. In the last 3 month period, DNA fell short of the market, returning -39.7%, while SPY returned +4.3%. However, in the most recent 2 weeks DNA has outperformed the stock market by returning +14.9%, while SPY returned +1.4%.

DNA support price is $9.20 and resistance is $9.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNA shares will trade within this expected range on the day.